177Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer
- PMID: 31546458
- DOI: 10.1016/j.msec.2019.110043
177Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer
Abstract
The gastrin-releasing peptide receptor (GRPr) is overexpressed in >75% of breast cancers. 177Lu-Bombesin (177Lu-BN) has demonstrated the ability to target GRPr and facilitate efficient delivery of therapeutic radiation doses to malignant cells. Poly(d,l‑lactide‑co‑glycolide) acid (PLGA) nanoparticles can work as smart drug controlled-release systems activated through pH changes. Considering that paclitaxel (PTX) is a first-line drug for cancer treatment, this work aimed to synthesize and chemically characterize a novel polymeric PTX-loaded nanosystem with grafted 177Lu-BN and to evaluate its performance as a targeted controlled-release nanomedicine for concomitant radiotherapy and chemotherapy of breast cancer. PLGA(PTX) nanoparticles were synthesized using the single emulsification-solvent evaporation method with PVA as a stabilizer in the presence of PTX. Thereafter, the activation of PLGA carboxylic groups for BN attachment through the Lys1-amine group was performed. Results of the chemical characterization by FT-IR, DLS, HPLC and SEM/TEM demonstrated the successful synthesis of BN-PLGA(PTX) with a hydrodynamic diameter of 163.54 ± 33.25 nm. The entrapment efficiency of paclitaxel was 92.8 ± 3.6%. The nanosystem showed an adequate controlled release of the anticancer drug, which increased significantly due to the pH change from neutral (pH = 7.4) to acidic conditions (pH = 5.3). After labeling with 177Lu and purification by ultrafiltration, 177Lu-BN-PLGA(PTX) was obtained with a radiochemical purity of 99 ± 1%. In vitro and in vivo studies using MDA-MB-231 breast cancer cells (GRPr-positive) demonstrated a 177Lu-BN-PLGA(PTX) specific uptake and a significantly higher cytotoxic effect for the radiolabeled nanosystem than the unlabeled BN-PLGA(PTX) nanoparticles. Using a pulmonary micrometastasis MDA-MB-231 model, the added value of 177Lu-BN-PLGA(PTX) for tumor imaging was confirmed. The 177Lu-BN-PLGA(PTX) nanomedicine is suitable as a targeted paclitaxel delivery system with concomitant radiotherapeutic effect for the treatment of GRPr-positive breast cancer.
Keywords: Cancer; Concomitant cancer treatment; Drug delivery; Radiotherapy; Smart nanoparticles; Targeted therapy.
Copyright © 2019. Published by Elsevier B.V.
Similar articles
-
Synthesis and Evaluation of 177Lu-DOTA-DN(PTX)-BN for Selective and Concomitant Radio and Drug-Therapeutic Effect on Breast Cancer Cells.Polymers (Basel). 2019 Sep 27;11(10):1572. doi: 10.3390/polym11101572. Polymers (Basel). 2019. PMID: 31569625 Free PMC article.
-
Folate-receptor-targeted laser-activable poly(lactide-co-glycolic acid) nanoparticles loaded with paclitaxel/indocyanine green for photoacoustic/ultrasound imaging and chemo/photothermal therapy.Int J Nanomedicine. 2018 Sep 6;13:5139-5158. doi: 10.2147/IJN.S167043. eCollection 2018. Int J Nanomedicine. 2018. PMID: 30233177 Free PMC article.
-
A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy.Acta Biomater. 2018 Oct 15;80:308-326. doi: 10.1016/j.actbio.2018.09.024. Epub 2018 Sep 19. Acta Biomater. 2018. PMID: 30240955
-
Aptamer-conjugated PLGA nanoparticles for delivery and imaging of cancer therapeutic drugs.Arch Biochem Biophys. 2020 Sep 30;691:108485. doi: 10.1016/j.abb.2020.108485. Epub 2020 Jul 24. Arch Biochem Biophys. 2020. PMID: 32712288 Review.
-
Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer.Biomolecules. 2019 Nov 27;9(12):789. doi: 10.3390/biom9120789. Biomolecules. 2019. PMID: 31783552 Free PMC article. Review.
Cited by
-
Development of 225Ac-doped biocompatible nanoparticles for targeted alpha therapy.J Nanobiotechnology. 2024 Jun 2;22(1):306. doi: 10.1186/s12951-024-02520-6. J Nanobiotechnology. 2024. PMID: 38825717 Free PMC article.
-
Towards Cancer Nanoradiopharmaceuticals-Radioisotope Nanocarrier System for Prostate Cancer Theranostics Based on Radiation-Synthesized Polymer Nanogels.Cancers (Basel). 2023 Nov 29;15(23):5646. doi: 10.3390/cancers15235646. Cancers (Basel). 2023. PMID: 38067350 Free PMC article.
-
GRPR-targeting radiotheranostics for breast cancer management.Front Med (Lausanne). 2023 Nov 3;10:1250799. doi: 10.3389/fmed.2023.1250799. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38020178 Free PMC article. Review.
-
Bombesins: A New Frontier in Hybrid Compound Development.Pharmaceutics. 2023 Nov 7;15(11):2597. doi: 10.3390/pharmaceutics15112597. Pharmaceutics. 2023. PMID: 38004575 Free PMC article. Review.
-
Therapeutic potential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment.Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):805-819. doi: 10.1007/s00259-023-06482-z. Epub 2023 Nov 7. Eur J Nucl Med Mol Imaging. 2024. PMID: 37932560
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous